(Total Views: 563)
Posted On: 08/28/2025 11:21:22 PM
Post# of 156689
Pfizer phase 3 sub-q PD-1 inhibitor -- Sasanlimab
Phase 3 trial (CREST), a combination of Sasanlimab and standard BCG treatment was shown to significantly improve event-free survival in patients with high-risk non-muscle invasive bladder cancer (NMIBC).
Results from early-stage studies also suggest potential efficacy in advanced urothelial cancer and other solid tumors.
32% improvement.
___
Uh oh Merck....we used your ICI in our 1st mTNBC 5 years ago, but is Cytodtn now considering Sasanlimab ???
Sure their 32% (68% failure) #'s would significantly improve with LL / Creativ-bio.
Dr. J mentioned Urothelial / bladder, as new eIND PD-L1 observation
These pharma titans are eventually going to clash.
Very typical...across industries.
Phase 3 trial (CREST), a combination of Sasanlimab and standard BCG treatment was shown to significantly improve event-free survival in patients with high-risk non-muscle invasive bladder cancer (NMIBC).
Results from early-stage studies also suggest potential efficacy in advanced urothelial cancer and other solid tumors.
32% improvement.
___
Uh oh Merck....we used your ICI in our 1st mTNBC 5 years ago, but is Cytodtn now considering Sasanlimab ???
Sure their 32% (68% failure) #'s would significantly improve with LL / Creativ-bio.
Dr. J mentioned Urothelial / bladder, as new eIND PD-L1 observation
These pharma titans are eventually going to clash.
Very typical...across industries.
(3)
(0)
